BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 17496165)

  • 1. A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation.
    Chapman RW; Minnicozzi M; Celly CS; Phillips JE; Kung TT; Hipkin RW; Fan X; Rindgen D; Deno G; Bond R; Gonsiorek W; Billah MM; Fine JS; Hey JA
    J Pharmacol Exp Ther; 2007 Aug; 322(2):486-93. PubMed ID: 17496165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist.
    Gonsiorek W; Fan X; Hesk D; Fossetta J; Qiu H; Jakway J; Billah M; Dwyer M; Chao J; Deno G; Taveras A; Lundell DJ; Hipkin RW
    J Pharmacol Exp Ther; 2007 Aug; 322(2):477-85. PubMed ID: 17496166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation.
    Planagumà A; Domènech T; Pont M; Calama E; García-González V; López R; Aulí M; López M; Fonquerna S; Ramos I; de Alba J; Nueda A; Prats N; Segarra V; Miralpeix M; Lehner MD
    Pulm Pharmacol Ther; 2015 Oct; 34():37-45. PubMed ID: 26271598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LPS challenge in healthy subjects: an investigation of neutrophil chemotaxis mechanisms involving CXCR1 and CXCR2.
    Aul R; Patel S; Summerhill S; Kilty I; Plumb J; Singh D
    Int Immunopharmacol; 2012 Jul; 13(3):225-31. PubMed ID: 22561413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutrophil chemotaxis caused by chronic obstructive pulmonary disease alveolar macrophages: the role of CXCL8 and the receptors CXCR1/CXCR2.
    Kaur M; Singh D
    J Pharmacol Exp Ther; 2013 Oct; 347(1):173-80. PubMed ID: 23912333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attenuation of leukocyte recruitment via CXCR1/2 inhibition stops the progression of PAH in mice with genetic ablation of endothelial BMPR-II.
    Burton VJ; Holmes AM; Ciuclan LI; Robinson A; Roger JS; Jarai G; Pearce AC; Budd DC
    Blood; 2011 Oct; 118(17):4750-8. PubMed ID: 21900197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects.
    Holz O; Khalilieh S; Ludwig-Sengpiel A; Watz H; Stryszak P; Soni P; Tsai M; Sadeh J; Magnussen H
    Eur Respir J; 2010 Mar; 35(3):564-70. PubMed ID: 19643947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist.
    Dwyer MP; Yu Y; Chao J; Aki C; Chao J; Biju P; Girijavallabhan V; Rindgen D; Bond R; Mayer-Ezel R; Jakway J; Hipkin RW; Fossetta J; Gonsiorek W; Bian H; Fan X; Terminelli C; Fine J; Lundell D; Merritt JR; Rokosz LL; Kaiser B; Li G; Wang W; Stauffer T; Ozgur L; Baldwin J; Taveras AG
    J Med Chem; 2006 Dec; 49(26):7603-6. PubMed ID: 17181143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non-competitive allosteric inhibitor.
    Bertini R; Barcelos LS; Beccari AR; Cavalieri B; Moriconi A; Bizzarri C; Di Benedetto P; Di Giacinto C; Gloaguen I; Galliera E; Corsi MM; Russo RC; Andrade SP; Cesta MC; Nano G; Aramini A; Cutrin JC; Locati M; Allegretti M; Teixeira MM
    Br J Pharmacol; 2012 Jan; 165(2):436-54. PubMed ID: 21718305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combined CXCR1/CXCR2 antagonist CXCL8(3-74)K11R/G31P blocks neutrophil infiltration, pyrexia, and pulmonary vascular pathology in endotoxemic animals.
    Gordon JR; Li F; Zhang X; Wang W; Zhao X; Nayyar A
    J Leukoc Biol; 2005 Dec; 78(6):1265-72. PubMed ID: 16204619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Administration of a CXC Chemokine Receptor 2 (CXCR2) Antagonist, SCH527123, Together with Oseltamivir Suppresses NETosis and Protects Mice from Lethal Influenza and Piglets from Swine-Influenza Infection.
    Ashar HK; Pulavendran S; Rudd JM; Maram P; Achanta M; Chow VTK; Malayer JR; Snider TA; Teluguakula N
    Am J Pathol; 2021 Apr; 191(4):669-685. PubMed ID: 33453177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Actin filaments are involved in the regulation of trafficking of two closely related chemokine receptors, CXCR1 and CXCR2.
    Zaslaver A; Feniger-Barish R; Ben-Baruch A
    J Immunol; 2001 Jan; 166(2):1272-84. PubMed ID: 11145710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of a CXCR1/CXCR2 antagonist on neutrophil migration in mild atopic asthmatic subjects.
    Todd CM; Salter BM; Murphy DM; Watson RM; Howie KJ; Milot J; Sadeh J; Boulet LP; O'Byrne PM; Gauvreau GM
    Pulm Pharmacol Ther; 2016 Dec; 41():34-39. PubMed ID: 27640067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gob-5 contributes to goblet cell hyperplasia and modulates pulmonary tissue inflammation.
    Long AJ; Sypek JP; Askew R; Fish SC; Mason LE; Williams CM; Goldman SJ
    Am J Respir Cell Mol Biol; 2006 Sep; 35(3):357-65. PubMed ID: 16645179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C(4)-alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists.
    Chao J; Taveras AG; Chao J; Aki C; Dwyer M; Yu Y; Purakkattle B; Rindgen D; Jakway J; Hipkin W; Fosetta J; Fan X; Lundell D; Fine J; Minnicozzi M; Phillips J; Merritt JR
    Bioorg Med Chem Lett; 2007 Jul; 17(13):3778-83. PubMed ID: 17459706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential activation and regulation of CXCR1 and CXCR2 by CXCL8 monomer and dimer.
    Nasser MW; Raghuwanshi SK; Grant DJ; Jala VR; Rajarathnam K; Richardson RM
    J Immunol; 2009 Sep; 183(5):3425-32. PubMed ID: 19667085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with DF 2162, a non-competitive allosteric inhibitor of CXCR1/2, diminishes neutrophil influx and inflammatory hypernociception in mice.
    Cunha TM; Barsante MM; Guerrero AT; Verri WA; Ferreira SH; Coelho FM; Bertini R; Di Giacinto C; Allegretti M; Cunha FQ; Teixeira MM
    Br J Pharmacol; 2008 May; 154(2):460-70. PubMed ID: 18362895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rabbit neutrophil chemotactic protein (NCP) activates both CXCR1 and CXCR2 and is the functional homologue for human CXCL6.
    Catusse J; Struyf S; Wuyts A; Weyler M; Loos T; Gijsbers K; Gouwy M; Proost P; Van Damme J
    Biochem Pharmacol; 2004 Nov; 68(10):1947-55. PubMed ID: 15476666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A potent and selective nonpeptide antagonist of CXCR2 inhibits acute and chronic models of arthritis in the rabbit.
    Podolin PL; Bolognese BJ; Foley JJ; Schmidt DB; Buckley PT; Widdowson KL; Jin Q; White JR; Lee JM; Goodman RB; Hagen TR; Kajikawa O; Marshall LA; Hay DW; Sarau HM
    J Immunol; 2002 Dec; 169(11):6435-44. PubMed ID: 12444152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The collagen-breakdown product N-acetyl-Proline-Glycine-Proline (N-alpha-PGP) does not interact directly with human CXCR1 and CXCR2.
    de Kruijf P; Lim HD; Overbeek SA; Zaman GJ; Kraneveld AD; Folkerts G; Leurs R; Smit MJ
    Eur J Pharmacol; 2010 Sep; 643(1):29-33. PubMed ID: 20599927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.